Cover Image

PD-1 and PD-L1 immune checkpoint blockade to treat breast cancer

Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especi...

Full description

Saved in:
Bibliographic Details
Main Authors: Hartkopf, Andreas (Author) , Taran, Florin-Andrei (Author) , Wallwiener, Markus (Author) , Walter, Christina B. (Author) , Krämer, Bernhard (Author) , Grischke, Eva-Maria (Author) , Brucker, Sara Y. (Author)
Format: Article (Journal)
Language:English
Published: December 8, 2016
In: Breast care
Year: 2016, Volume: 11, Issue: 6, Pages: 385-390
ISSN:1661-3805
DOI:10.1159/000453569
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1159/000453569
Verlag, lizenzpflichtig, Volltext: https://www.karger.com/Article/FullText/453569
Get full text
Author Notes:Andreas D. Hartkopf, Florin-Andrei Taran, Markus Wallwiener, Christina B. Walter, Bernhard Krämer, Eva-Maria Grischke, Sara Y. Brucker
Description
Summary:Immune checkpoint inhibition represents a major recent breakthrough in the treatment of malignant diseases including breast cancer. Blocking the programmed death receptor-1 (PD-1) and its ligand, PD-L1, has shown impressive antitumor activity and may lead to durable long-term disease control, especially in the triple-negative subtypes of breast cancer (TNBC). Although immune checkpoint blockade is generally well tolerated, specific immune-related adverse events (irAEs) may occur. This review summarizes the clinical efficacy, perspectives, and future challenges of using PD-1/PD-L1-directed antibodies in the treatment of breast cancer.
Item Description:Gesehen am 30.04.2020
Physical Description:Online Resource
ISSN:1661-3805
DOI:10.1159/000453569

Similar Items